Loading
Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery.
Jeanne Tie led DYNAMIC, which showed that using ctDNA to decide adjuvant chemotherapy in stage II colon cancer halves chemotherapy use without worsening recurrence-free survival, the first randomised proof that ctDNA-guided de-escalation works. Her 2016 study established post-operative ctDNA as a powerful marker of residual disease. She now leads DYNAMIC-III and DYNAMIC-Rectal.
| Title | Journal | Year |
|---|---|---|
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC) | NEJM | 2022 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine | 2016 |
| GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold | Nature Medicine | 2023 |
The blood test stratifies risk far better than stage or pathology. It supports treating ctDNA-positive patients and suggests ctDNA-negative patients gain little from chemotherapy, but because treatment was not randomised the de-escalation claim needs the randomised trials that are now under way.
For stage II colon cancer, where most patients are cured by surgery alone, a blood test can identify the minority who benefit from chemotherapy and spare everyone else its side effects. It does not yet prove that treating ctDNA-positive patients improves survival compared with not treating them.
Postoperative ctDNA marks a group that current adjuvant chemotherapy does not cure, the rationale for ctDNA-guided intensification trials.
Minimal residual disease became measurable in solid tumours, and the DYNAMIC and CIRCULATE trials that followed turned the measurement into a treatment decision.
Shares GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC.
Shares Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Colorectal cancer and the tags ctdna, colorectal.
Shares GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Signatera.
Shares Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, DYNAMIC.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag ctdna.
Shares Colorectal cancer and the tags colorectal, de-escalation.
Shares Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer and the tag ctdna.